Therefore, V-aCD3 is ultimately a trispecific molecule that can bind target tumor cells via rVAR2, recruit and activate T cells via the anti-CD3 domain, and bind FcγR and mediate additional Fc-dependent killing capabilities, such as antibody-dependent cellular cytotoxicity (ADCC) through activation of Fc receptor-expressing cells42,43. This evidence concerns the gene FCGR2A and neoplasm.